Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TauroLock-U25000 vs TauroLock-Hep500 for Catheter Thrombosis in Hemodialysis
NCT02868697Phase 4Completed
- Sponsor
- Hamad Medical Corporation
- Start
- Nov 2013
- Primary completion
- Aug 2015
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of urokinase in catheter-related thrombosis (CRT) (2 arms), sponsored by Hamad Medical Corporation. Primary endpoint: Number of catheter thrombosis episodes at 6 months. Started Nov 2013; status: completed.
02
Drugs
urokinase
03
Conditions
catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on NCT02868697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868697.